Kornimate/medical-research-clean huggingface dataset:
effects on glucose homeostasis of changes in plasma lipoproteins induced by nutritional and pharmacologic strategies

Conditions: Glucose Metabolism Disorders

Summary: the investigators aim to examine the impact of changes in plasma lipoproteins induced by nutritional and pharmacological interventions on glucose homeostasis


Eligibility criteria:
inclusion criteria: * age 18-65 years * both males and females exclusion criteria: * acute or chronic conditions influencing glucose and lipid metabolism * pregnancy
tau pet imaging in the aging brain cohort dedicated to diversity study

Conditions: Cognitive Decline; Alzheimer Disease

Summary: we will conduct a tau pet scan in cognitively normal older adults, enrolled in the aging brain cohort dedicated to diversity study (abcd2-tau) study at the university of pennsylvania's penn memory center/alzheimer's disease core center (pmc/adc).study duration will generally be a one-day study visit for pet imaging, but all subjects will be followed annually as part of their participation in the abcd2 study. findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical alzheimer's disease.


Eligibility criteria:
inclusion criteria: 1. males and females african americans ≥ 65 years of age. 2. part of the abcd2 longitudinal cohort, protocol 844047, of the pmc/adcc with consensus conference designation of normal cognition. 3. abcd2 longitudinal visit must be completed or scheduled to be completed within 1 year prior to the \[18f\]av-1451 tau pet scan. 4. a brain mri must be performed within 1 year prior to their study \[18f\]av-1451 tau pet scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3t high-resolution imaging of medial temporal lobe structures. 5. an amyloid pet scan completed or scheduled within 1year of their study \[18f\]av-1451 6. women must be post-menopausal or surgically sterile. exclusion criteria: 1. have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, including major depression and prior head trauma. 2. have evidence of structural abnormalities such as major stroke or mass on mri that is likely to interfere with analysis of the pet scan. 3. inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. 4. have a history of significant ongoing alcohol or substance abuse or dependence based on self-report. 5. women of child bearing potential * the inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (epic or the adc database)\*

Keywords: healthy subjects
effects of heart imaging radiation on dna double-stranded breaks in blood lymphocytes and hair follicle cells

Conditions: Coronary Artery Disease; Chest Pain

Summary: purpose 1. to investigate the effects of cardiac imaging radiation on the induction of dna double-strand breaks by enumerating gamma-h2ax foci in blood lymphocytes and plucked hair follicle cells. 2. to estimate whether the use of breast shields in cardiac computed tomographic angiography (ccta) limits the effective radiation exposure of breast tissue.

the primary objective of the study is to analyze blood and hair samples from patients undergoing cardiac imaging to estimate radiation exposure levels as well as their biological effects (i.e. to determine the degree of genotoxicity by measuring the amounts of dna double-strand breaks). the secondary objective is to investigate whether the use of in-plane breast shielding in female patients undergoing ct angiography (ccta) limits the radiation exposure of breast tissue and subsequent dna damage in blood lymphocytes and hair follicle cells.

Eligibility criteria:
inclusion criteria: * adult male and female adult subjects (age greater than 18 years) * referred for cardiac computed tomography angiography (ccta), myocardial perfusion scintigraphy (mps), or diagnostic invasive coronary angiography (ica). exclusion criteria: * female patients that identify themselves as pregnant or have a positive pregnancy test prior to cardiac imaging. * history (present or past) of leukemia or lymphoma. * history of radiation therapy * x-ray examination or scintigraphy within the last 72 hours. * history of coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention) * patients undergoing percutaneous coronary intervention at completion of diagnostic left heart catheterization

Keywords: radiation cardiac computed tomography ccta breast shielding myocardial perfusion scintigraphy mps invasive coronary angiography ica
injectable diclofenac for the prevention of post-operative dental pain

Conditions: Pain

Summary: this is a prospective, randomised, double-blind, placebo-controlled, parallel group study in approximately 75 patients undergoing surgical removal of an impacted lower third molar.


Eligibility criteria:
inclusion criteria: 1. out-patients of either gender. 2. patients aged ≥ 18 to ≤ 65 years old. 3. subjects able and willing to give their written consent prior to inclusion in the study. 4. female subjects of childbearing potential must (1) have a negative urine pregnancy test at the inclusion visit, (2) be using an appropriate method of contraception according to the definition of note of ich m3 guideline (implants, injectables, combined oral contraceptives, some iuds, sexual abstinence or vasectomised partner), and (3) be willing to continue using the contraceptive method throughout the entire study period. 5. subjects must (1) be able to comprehend the full nature and purpose of the study, including possible risks and side effects, (2) fully co-operate with the investigator, (3) comply with the requirements of the entire study. 6. patients undergoing surgical extraction of a single, fully or partially impacted mandibular 3rd molar requiring bone removal. exclusion criteria: general 1. patients refusing to give written informed consent. 2. patients not able to understand the purposes of the study or not willing to return for the control visits. 3. patients with major psychiatric disorders that, in the investigator's opinion, could compromise study participation. 4. patients enrolled in any clinical trial in the previous 3 months. 5. employees of the study centre with direct involvement in the proposed study or other studies under the direction of the main investigator or study centre, as well as family members of the employees or investigator. 6. pregnant or breast-feeding women. 7. alcohol or drug abuse in the previous 12 months. 8. clinically significant or unstable concomitant disease whose sequelae might interfere with the study evaluation parameters.

Keywords: diclofenac, postsurgical pain, oral surgery
effect of bmi on postoperative morbidities of orthopaedic procedures

Conditions: Orthopedic Procedures; Obesity

Summary: obesity is associated with poor surgical outcome and complications. the literature does not provide a comprehensive view on the effect of body mass index (bmi) on perioperative outcomes in orthopedic surgeries. therefore, we aim to determine the effect of bmi on 30-day perioperative outcomes in patients undergoing the first 25 most commonly performed orthopedic surgeries using a retrospective cohort study design. the knowledge of the effect of bmi on orthopedic surgeries will improve the knowledge of surgeons about the expected morbidities.

obesity is associated with poor surgical outcome and complications. the literature does not provide a comprehensive view on the effect of body mass index (bmi) on perioperative outcomes in orthopedic surgeries. therefore, we aim to determine the procedure specific, independent-effect of bmi on 30-day perioperative outcomes in patients undergoing the first 25 most commonly performed orthopedic surgeries. the study is a retrospective cohort study. the subjects will be the individuals undergoing one of first 25 most commonly performed orthopedic surgeries, whose information is derived form the de-identified patients' data collected through the american college of surgeons national surgical quality improvement program (acs-nsqip) database. the primary outcome will be composite post-operative morbidity. specific morbidities will also be evaluated including cardiovascular, vascular and renal complications, length-of-stay (los), and the need for re-intervention and readmission, as well as 30-day mortality. descriptive statistics and multivariable regression models will assess the independent-effect of bmi on outcomes. the knowledge of the effect of bmi on orthopedic surgeries will improve the knowledge of surgeons about the expected morbidities. the surgeon will be able to better counsel obese patients and devise a better surgical plan to prevent or deal with the expected outcomes.

Eligibility criteria:
inclusion criteria: * the inclusion and exclusion criteria are the same as that of acs-nsqip database. * all patients who have undergone any of the 25 most common orthopedic procedures as primary procedure as identified through the cpt codes exclusion criteria: * all patients whose bmi was not reported

Keywords: weight orthopedic surgery bmi post-op complication
recombinant human c1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema

Conditions: Genetic Disorders

Summary: the purpose of this multi-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human c1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.


Eligibility criteria:
main inclusion criteria: * clinical and laboratory diagnosis of hae * plasma level of functional c1inh of less than 50% of normal * severe attack of abdominal, facial-oro-pharyngeal, genito-urinary and/or peripheral hae. main exclusion criteria: * acquired angioedema * pregnancy or breastfeeding * participation in another clinical study within prior 3 months
antibiotic resistant helicobacter pylori in rajavithi hospital

Conditions: Dyspepsia

Summary: peptic ulcer disease is the most common gastrointestinal disease. antibiotic resistant helicobacter pylori is a major problem worldwide. the gold standard for helicobacter pylori eradication is composed of proton-pump inhibitor/ranitidine bismuth citrate + amoxycillin + metronidazole /clarithromycin. in thailand, clarithromycin resistant strains increased and led to treatment failure. data on file at rajavithi hospital showed that metronidazole resistant h. pylori was about 50% and clarithromycin resistant strains accounted for 8%. this molecular genetic study will be performed in patients presenting with dyspepsia, who had an indication for gastroscopic examination, to explore the incidence of antibiotic resistant helicobacter pylori in rajavithi hospital, thailand.

genetic and biomolecular factors determining clarithromycin resistance will be characterized.

Eligibility criteria:
inclusion criteria: * male or female with dyspepsia * age \> 15 years * fulfil indication for gastroscopic examination * able to give informed consent exclusion criteria: * contraindication for gastroscopic examination and biopsy

Keywords: h. pylori, clarithromycin resistant, gene
frequency of icam-1 polymorphisms in obese subjects

Conditions: Obesity

Summary: the genetic contribution to the development of obesity is now well recognized. however obesity is a polygenic disease and thus many genes are likely to be involved. this study aims to investigate the possible association between specific variants of the gene coding for the intercellular adhesion molecule-1 (icam-1)and the development of severe obesity in an italian population

severely obese subjects referred to our institution will be evaluated. for the aim of the study, a venous blood sample will be obtained from these subjects and from a group of normal weight volunteers. genomic dna will be extracted from the blood samples and analysed by standard molecular biology techniques.the allelic and genotype frequencies of the two icam-1 variants will be calculated in the obese and control groups. the statistical significance of possible differences will be determined

Eligibility criteria:
inclusion criteria: * obesity exclusion criteria: * associated inflammatory diseases

Keywords: icam-1 obesity gene variants
reproductive outcome in assisted conception cycles

Conditions: Infertility

Summary: infertility is the failure to conceive after regular unprotected sexual intercourse for one year. primary infertility refers woman who has never conceived, and secondary infertility to one who has had a previous pregnancy.the most frequent causes for infertility are ovulatory disorder or anovulation (27-30%) , tubal factor(20-22%), abnormal semen parameters(45-50%). unexplained infertility refers to infertile couples in whom standard investigations, including tests of ovulation, tubal patency tests and semen analysis are normal. incidence 15-17% of infertile couples. new guidelines on infertility recommend that women with unexplained infertility should be advised for expectant management for 2 years .if pregnancy is not achieved after this period in vitro fertilization should be considered. the fast track and standard treatment trial demonstrated a shorter time to pregnancy and higher per cycle pregnancy rates for in vitro fertilization compared with treatment with oral agents or gonadotropins in patients with unexplained infertility. successful pregnancy after assisted reproductive technology is influenced by numerous predictors that have been investigated in the previous years. the central predictors of success are the sperm, oocyte quality and endometrial receptivity. oocyte quality depends mainly on the age of the woman , and her ovarian reserve. parameters most commonly studied are the woman's age , her antral follicle count , and laboratory tests including serum randomly done during the menstrual cycle levels at day 3 of the cycle.


Eligibility criteria:
inclusion criteria: * in vitro fertilization treatment due to many factors including tubal, male, and unexplained factors. * body mass index (bmi) (18-35)kg/m2 exclusion criteria 1. patient age less than 20 and more than 40 years. 2. body mass index less than 18 and more than 35 kg/m2. 3. period of infertility less than 2 years.. 4. untreated hyperthyroidism, hypothyroidism, diabetes, hypertension.
polaris - crestor 40 mg vs atorvastatin 80 mg for 26 weeks

Conditions: Hypercholesterolemia; Coronary Heart Disease

Summary: the purpose of this study is to compare the effect of 8 weeks of treatment with rosuvastatin with 8 weeks of treatment with atorvastatin on low density lipoprotein cholesterol level in subjects with hypercholesterolemia and coronary heart disease (chd) or at high risk of chd..


Eligibility criteria:
inclusion criteria: * a history of chd or clinical evidence of atherosclerosis or multiple risk factors that confer a high risk as defined in the protocol. * fasting ldl-c concentrations at visit 1 as defined in the protocol. exclusion criteria: * history of statin induced serious side effects, or serious hypersensitivity reaction to other statins. * subjects considered to be unstable by the investigator after the following events: a myocardial infarction (heart attack), unstable angina, myocardial revascularisation or another revascularisation procedure or a transient ischaemic attack (tia) or stroke. * severe congestive cardiac failure (as defined by the protocol - appendix i). * subjects awaiting a planned myocardial revascularisation prior to starting the study (i.e. planned prior to visit 1).

Keywords: cholesterol low density lipoproteins hypercholesterolemia coronary heart disease rosuvastatin crestor atorvastatin lipitor
comparing the effectiveness and safety of 2 doses of an experimental drug, cp-690,550, to methotrexate (mtx) in patients with rheumatoid arthritis who have not previously received mtx

Conditions: Arthritis, Rheumatoid

Summary: this study is designed to compare the effectiveness of the experimental drug, cp-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. this study will also compare the safety of cp-690,550 with methotrexate.


Eligibility criteria:
inclusion criteria: * adults with moderate to severe ra (rheumatoid arthritis) who have not been treated with methotrexate. * diagnosis of ra based on the american college of rheumatology 1987 revised criteria. * active disease as defined by both \>=6 tender or painful joints on motion and \>= 6 joints swollen; and either an erythrocyte sedimentation rate (esr) \> 28 mm or a c-reactive protein (crp) concentration \> 7 mg/dl exclusion criteria: * blood dyscrasias including confirmed: hemoglobin \<9 g/dl or hematocrit \<30%; white blood cell count \<3.0 x 109/l; absolute neutrophil count \<1.2 x 109/l; platelet count \<100 x 109/l * history of any other rheumatic autoimmune disease other than sjogren's syndrome * no malignancy or history of malignancy * history of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug * no chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy

Keywords: oral jak inhibitor mtx dmard clinical trial joint diseases autoimmune diseases anti-inflammatory agents rheumatic diseases
effects of brain beta-amyloid on postoperative cognition

Conditions: Postoperative Cognitive Dysfunction

Summary: postoperative cognitive decline (pocd) affects up to 50% of non-cardiac surgical patients greater than or equal to 65 years of age. this study will test the hypothesis that preoperative presence of brain beta-amyloid plaques in non-demented subjects increases postoperative cognitive decline (pocd) in elderly subjects scheduled for hip or knee replacement. the investigators hypothesize that preoperative beta-amyloid plaques will predict postoperative cognitive decline.


Eligibility criteria:
inclusion criteria: * scheduled for total knee arthroplasty or total hip arthroplasty under general anesthesia (primary arthroplasties and revisions) * english speaking * anticipated stay in the hospital * not anticipated to stay intubated postoperatively * patients who live with or have regular visits from an individual ("study partner") willing to provide information about the patient's cognitive status * willing and able to undergo all testing procedures including neuroimaging and agree to longitudinal follow up * adequate visual and auditory acuity to allow neuropsychological testing * subjects with clinical dementia rating scale (cdr) of 0-0.5 * patients who are not demented * subjects sho signed an irb approved informed consent prior to any study procedures exclusion criteria: * clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances as indicated by history, which in the opinion of the investigator might pose a potential safety risk to the subject * current clinically significant cardiovascular disease. * history of drug or alcohol abuse within the last year, or prior prolonged history of abuse * clinically significant infections disease, including acquired immune deficiency syndrome (aids) or human immunodeficiency virus (hiv) infection or previous positive test for hepatitis * history of relevant severe drug allergy or hypersensitivity * received an investigational medication under an fda ind protocol within the last 30 days. * current clinically significant unstable medical comorbidities, as indicated by history or physical exam, that pose a potential safety risk to the subject * received a radiopharmaceutical for imaging or therapy within the past 24 hours prior to the imaging session for this study * severe psychiatric disorders including schizophrenia, bipolar disorders, and major depression as described in dsm-iv within the past year (medical record, gds score, interview with the patient and study partner) * obvious causes for their cognitive impairment (e.g. onset coincides with recent head trauma or stroke) * dementia of any cause * cdr score \> 0.5 * expressed the preference to undergo the procedure under regional anesthesia in form of spinal or epidural anesthesia * patients who, in the opinion of the investigator, are otherwise unsuitable for a study of this type

Keywords: postoperative cognitive dysfunction postoperative cognitive decline pocd alzheimer's disease florbetapir f 18 (18f-av-45)
study to investigate the efficacy, safety and tolerability of azd1152 alone and in combination with low dose cytosine arabinoside (ldac)in acute myeloid leukaemia (aml) patients

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to assess the efficacy, safety and tolerability of azd1152 alone and in combination with low dose cytosine arabinoside (ldac) in comparison with ldac alone in aml patients.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * newly diagnosed male or female patients aged 60 and over * de novo or secondary aml * not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following:age ≥75 years; adverse cytogenetics, e.g., as defined by the mrc prognostic groupings; who performance status \>2; organ dysfunction arising from significant co-morbidities not directly linked to leukaemia exclusion criteria: * participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product * administration of ldac is clinically contraindicated * patients with aml of fab m3 classification acute promyelocytic leukaemia (apl) * patients with blast crisis of chronic myeloid leukaemia

Keywords: acute myeloid leukaemia, aml